Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced
nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or
highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1
based on the available data in the literature as well as the recommendations provided by
established guidelines